Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression

Brain Research

Volumn 976, Issue 1, 2003, Pages 1-8

  Uzunova, Veska ^a   Ceci, Melanie ^a   Kohler, Christian ^a   Uzunov, Doncho P ^a   Wrynn, Aileen S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Allopregnanolone; Amygdala; Animal model of depression; Neurosteroid; Olfactory bulbectomy

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; FRONTAL CORTEX; GABAERGIC SYSTEM; HIPPOCAMPUS; HOMEOSTASIS; HORMONAL REGULATION; HORMONE DETERMINATION; MALE; NONHUMAN; OLFACTORY BULBECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SYNDROME;

EID: 0038743129     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(03)02577-0     Document Type: Article

References (53)

1. Akwa Y., Purdy R.H., Koob G.F., Britton K.T. The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav. Brain Res. 106:1999;119-125.
2. Cheney D.L., Uzunov D., Costa E., Guidotti A. Gas chromatographic-mass fragmentographic quantitation of 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) and its precursors in blood and brain of adrenalectomized and castrated rats. J. Neurosci. 15:1995;4641-4650.
3. Cheng K.-C., Lee J., Khanna M., Qin K.-N. Distribution and ontogeny of 3α-hydroxysteroid dehydrogenase in the rat brain. J. Steroid Biochem. Mol. Biol. 50:1994;85-89.
4. Cryan J.F., McGrath C., Leonard B.E., Norman T.R. Combining pindolol and paroxetine in an animal model of chronic antidepressant action - can early onset of action be detected? Eur. J. Pharmacol. 352:1998;23-28.
5. Cryan J.F., McGrath C., Leonard B.E., Norman T.R. Onset of the effects of the 5-HT1A antagonist, WAY-100635, alone, and in combination with paroxetine, on olfactory bulbectomy and 8-OH-DPAT-induced changes in the rat. Pharmacol. Biochem. Behav. 63:1999;333-338.
6. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23:2002;238-245.
7. Davis M. The role of the amygdala in conditioned fear. Aggleton J.P. The Amygdala: Neurobiological Aspects of Emotion. 1992;255-305 Wiley-Liss, New York.
8. Drevets W.C. Neuroimaging of mood disorders. Biol. Psychiatry. 48:2000;813-829.
9. Drevets W.C. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. 11:2001;240-249.
10. Frye C.A., Walf A.A. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. Horm. Behav. 41:2002;306-315.
11. Gasior M., Carter R.B., Witkin J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci. 20:1999;107-112.
12. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psychiatry. 49:2001;788-797.
13. Grecksch G., Zhou D., Franke C., Schröder U., Bernhard S., Becker A., Huether G. Influence of olfactory bulbectomy and subsequent imipramine treatment on 5-hydroxytryptaminergic presynapses in the rat frontal cortex: behavioral correlates. Br. J. Pharmacol. 122:1997;1725-1731.
14. Guidotti A., Dong E., Matsumoto K., Pinna G., Rasmusson A.M., Costa E. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res. Rev. 37:2001;110-115.
15. Jesberger J.A., Richardson J.S. Animal models of depression: parallels and correlates to severe depression in humans. Biol. Psychiatry. 20:1985;764-784.
16. Jesberger J.A., Richardson J.S. Brain output dysregulation induced by olfactory bulbectomy: an approximation in the rat of major depressive disorder in humans? Int. J. Neurosci. 38:1988;241-265.
17. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther. 74:1997;299-316.
18. Khisti R.T., Chopde C.T. Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice. Brain Res. 865:2000;291-300.
19. Khisti R.T., Chopde C.T., Jain S.P. Antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav. 67:2000;137-143.
20. Krieger N.R., Scott R.G. 3α-Hydroxysteroid oxidoreductase in rat brain. J. Neurochem. 42:1984;887-890.
21. A receptor function. Trends Pharmacol. Sci. 16:1995;295-303.
22. LeDoux J.E. Emotion circuits in the brain. Annu. Rev. Neurosci. 23:2000;155-184.
23. Le Melledo J.-M., Baker G.B. Neuroactive steroids and anxiety disorders. J. Psychiatry Neurosci. 27:2002;161-165.
24. Leonard B.E., Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int. Rev. Neurobiol. 22:1981;251-286.
25. Li X., Bertics P.J., Karavolas H.J. Regional distribution of cytosolic and particulate 5α-dihydroprogesterone 3α-hydroxysteroid oxidoreductases in female rat brain. J. Steroid Biochem. Mol. Biol. 60:1997;311-318.
26. Lloyd K.G., Garrigou D., Broekkamp C.L.E. The action of monoaminergic, cholinergic and GABAergic compounds in the olfactory bulbectomized rat model of depression. Langer S.Z., Takahasini R., Segawas T., Briley M. New Vistas in Depression. 1982;179-186 Pergamon Press, New York.
27. Lumia A.R., Lebrowski A.F., McGinnis M.Y. Olfactory bulb removal decreases androgen receptor binding in amygdala and hypothalamus and disrupts masculine sexual behavior. Brain Res. 404:1987;121-126.
28. Lumia A.R., Teicher M.H., Salchli F., Ayers E., Possidente B. Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res. 587:1992;181-185.
29. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
30. Matsumoto K., Uzunova V., Pinna G., Taki K., Uzunov D.P., Watanabe H., Mienville J.-M., Guidotti A., Costa E. Permissive role of brain allopregnanolone content in the regulation of pentobarbital-induced righting reflex loss. Neuropharmacology. 38:1999;955-963.
31. McNish K.A., Davis M. Olfactory bulbectomy enhances sensitization of the acoustic startle reflex produced by acute or repeated stress. Behav. Neurosci. 111:1997;80-91.
32. Mellon S.H., Griffin L.D. Neurosteroids: biochemistry and clinical significance. Trends Endocrinol. Metab. 13:2002;35-43.
33. O'Connor W.T., Earley B., Leonard B.E. Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolam: studies in the olfactory bulbectomized rat model of depression. Br. J. Clin. Pharmacol. 19:1985;45S-56S.
34. Paul S.M., Purdy R.H. Neuroactive steroids. FASEB J. 6:1992;2311-2322.
35. Pause B.M., Miranda A., Goeder R., Aldenhoff J.B., Ferstl R. Reduced olfactory performance in patients with major depression. J. Psychiatr. Res. 35:2001;271-277.
36. A receptor agonist muscimol. Neuropharmacology. 39:2000;440-448.
37. Purdy R.H., Morrow A.L., Moore Jr P.H., Paul S.M. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA. 88:1991;4553-4557.
38. Rapkin A.J., Morgan M., Goldman L., Bran D.W., Simone D., Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90:1997;709-714.
39. Romeo E., Stroehle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 155:1998;910-913.
40. Rupprecht R., di Michele F., Hermann B., Stroehle A., Lancel M., Romeo E., Holsboer F. Neuroactive steroids: molecular mechanisms of action and implications for neuropsychopharmacology. Brain Res. Rev. 37:2001;59-67.
41. Rupprecht R., Holsboer F. Neuropsychopharmacological properties of neuroactive steroids. Steroids. 64:1999;83-91.
42. Rupprecht R., Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22:1999;410-416.
43. A receptors in the rat amygdala. Pharmacol. Biochem. Behav. 52:1995;701-706.
44. A receptor function in rat brain. J. Neurochem. 75:2000;732-740.
45. Sieck M.H., Baumbach H.D., Gordon B.L., Turner J.F. Changes in spontaneous odor modulated and shock induced behavioural patterns following discrete olfactory system lesions. Physiol. Behav. 13:1974;427-439.
46. Stroehle A., Romeo E., Hermann B., Pasini A., Spalletta G., di Michele F., Holsboer F., Rupprecht R. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol. Psychiatry. 45:1999;274-277.
47. Uzunov D.P., B Cooper T., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. USA. 93:1996;12599-12604.
48. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. USA. 95:1998;3239-3244.
49. Wang M., Seippel L., Purdy R.H., Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5α-pregnane-3,20-dione and 3α-hydroxy-5α-pregnan-20-one. J. Clin. Endocrinol. Metab. 81:1996;1076-1082.
50. Williams G.W., Goldman J., Mc Ginnis M.Y., Possidents B., Lumia A.R. Effects of ovarian hormones on sexual receptivity, proceptivity, and motivation in olfactory bulbectomized female rats. Physiol. Behav. 50:1991;751-755.
51. Willner P., Mitchell P.J. The validity of animal models of predisposition to depression. Behav. Pharmacol. 13:2002;169-188.
52. Wrynn A.S., MacSweeney C.P., Franconi F., Lemaire L., Pouliquen D., Herlidou S., Leonard B.E., Gandon J.-M., de Certaines J.D. An in-vivo magnetic resonance study of the olfactory bulbectomized rat model of depression. Brain. Res. 879:2000;193-199.
53. Zorumski C.F., Mennerick S., Isenberg K.E., Covey D.F. Potential clinical use of neuroactive steroids. Curr. Opin. Invest. Drugs. 1:2000;360-369.